NOMAD POWER SOLUTIONS INC
NMADNASDAQπ #4206 by market capUS Equity
$2.57β² $0.25 (+10.78%)
Market closed Β· at closeTrack NMAD
Get earnings, price moves & breaking news on Telegram
24hβ² 10.8%
7dβ² 10.8%
14dβΌ 29.0%
30dβΌ 32.9%
ytdβΌ 34.4%
1yβΌ 40.8%
π¦Market Cap
$41M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $2.23 β $2.57
- 52-Week Range
- $2.15 β $7.70
- Volume (shares)
- 9,270
- Avg Volume (shares)
- β
- Shares Outstanding
- 16.1M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $472,000
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-0.98
- Dividend Yield
- β
- Dilution (1yr)
- +244.5%
NOMAD POWER SOLUTIONS INC
NMADFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$5Mβ² +43.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$3MβΌ β3.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
7.7Mβ² +244.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4Mβ² +$3M YoY
About NOMAD POWER SOLUTIONS INC
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.